{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:08Z","timestamp":1791827588948,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00869-5","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:26Z","timestamp":1789549346000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-guided cardioprotection in cardio-oncology"],"prefix":"10.1038","volume":"5","author":[{"given":"Kai Yi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-0404","authenticated-orcid":false,"given":"Dae Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Kuppusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6628-9981","authenticated-orcid":false,"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"869_CR1","first-page":"308","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle, N. S. et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J. Clin. 75, 308\u2013340 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"869_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom, M. W. et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J. Card. Fail. 31, 415\u2013455 (2025).","journal-title":"J. Card. Fail."},{"key":"869_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","volume":"7","author":"A Ali","year":"2025","unstructured":"Ali, A. et al. Risk stratification for trastuzumab-induced cardiac dysfunction and potential implications for surveillance. JACC CardioOncol 7, 203\u2013215 (2025).","journal-title":"JACC CardioOncol"},{"key":"869_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","volume":"46","author":"B Rivero-Santana","year":"2025","unstructured":"Rivero-Santana, B. et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur. Heart J. 46, 273\u2013284 (2025).","journal-title":"Eur. Heart J."},{"key":"869_CR5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell, R. F. et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J. Clin. Oncol. 37, 1946\u20131955 (2019).","journal-title":"J. Clin. Oncol."},{"key":"869_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaccao.2025.02.005","volume":"7","author":"O Itzhaki Ben Zadok","year":"2025","unstructured":"Itzhaki Ben Zadok, O., O\u2019Hare, M. J. & Nohria, A. Immune checkpoint inhibitor\u2013related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes. JACC CardioOncol 7, 252\u2013264 (2025).","journal-title":"JACC CardioOncol"},{"key":"869_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.6004\/jnccn.2023.7047","volume":"21","author":"V Narayan","year":"2023","unstructured":"Narayan, V. et al. Early increases in blood pressure and major adverse cardiovascular events in patients with renal cell carcinoma and thyroid cancer treated with VEGFR TKIs. J. Natl Compr. Canc. Netw. 21, 1039\u20131049 (2023).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"869_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaccao.2025.01.012","volume":"7","author":"E Berlin","year":"2025","unstructured":"Berlin, E. et al. Cardiac effects of modern breast radiation therapy in patients receiving systemic cancer therapy. JACC CardioOncol 7, 219\u2013230 (2025).","journal-title":"JACC CardioOncol"},{"key":"869_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian, S. H. et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J. Clin. Oncol. 34, 1122\u20131130 (2016).","journal-title":"J. Clin. Oncol."},{"key":"869_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.18.00313","volume":"37","author":"KD Getz","year":"2019","unstructured":"Getz, K. D. et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 37, 12\u201321 (2019).","journal-title":"J. Clin. Oncol."},{"key":"869_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","volume":"1","author":"M Vaduganathan","year":"2019","unstructured":"Vaduganathan, M. et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 1, 54\u201365 (2019). Neurohormonal antagonists are associated with a modest preservation of LVEF (3.96%).","journal-title":"JACC CardioOncol"},{"key":"869_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland, T., Heck, S. L. & Gulati, G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 4, 19\u201337 (2022).","journal-title":"JACC CardioOncol."},{"key":"869_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","volume":"6","author":"Z Raisi-Estabragh","year":"2024","unstructured":"Raisi-Estabragh, Z. et al. Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: CardioOncology Expert Panel recommendations. JACC CardioOncol. 6, 631\u2013654 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck, S. L. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 143, 2431\u20132440 (2021).","journal-title":"Circulation"},{"key":"869_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","volume":"152","author":"T Omland","year":"2025","unstructured":"Omland, T. et al. Sacubitril\/valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial. Circulation 152, 1136\u20131145 (2025).","journal-title":"Circulation"},{"key":"869_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105116","volume":"10","author":"I Meattini","year":"2025","unstructured":"Meattini, I. et al. Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 \u00d7 2 randomized, placebo-controlled, double-blind SAFE trial. ESMO Open 10, 105116 (2025).","journal-title":"ESMO Open"},{"key":"869_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","volume":"6","author":"D Austin","year":"2024","unstructured":"Austin, D. et al. Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial. JACC CardioOncol. 6, 684\u2013696 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan, T. G. et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330, 528\u2013536 (2023).","journal-title":"JAMA"},{"key":"869_CR19","doi-asserted-by":"publisher","unstructured":"Hundley W. G., et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. 1, 9 https:\/\/doi.org\/10.1056\/evidoa2200097 (2022).","DOI":"10.1056\/evidoa2200097"},{"key":"869_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon, A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 22, 1945\u20131960 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"869_CR21","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R. et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur. Heart J. 43, 4229\u20134361 (2022).","journal-title":"Eur. Heart J."},{"key":"869_CR22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin, M. et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J. Am. Coll. Cardiol. 73, 2859\u20132868 (2019). Among patients with HER2-positive breast cancer, lisinopril and carvedilol reduced the risk of CTRCD in patients who received anthracycline followed by trastuzumab (a high-risk group).","journal-title":"J. Am. Coll. Cardiol."},{"key":"869_CR23","first-page":"E895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, E895\u2013E1032 (2022).","journal-title":"Circulation"},{"key":"869_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge, M. et al. Natriuretic peptide\u2013based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310, 66\u201374 (2013).","journal-title":"JAMA"},{"key":"869_CR25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","volume":"62","author":"M Huelsmann","year":"2013","unstructured":"Huelsmann, M. et al. PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. J. Am. Coll. Cardiol. 62, 1365\u20131372 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"869_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian, S. H. et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 35, 893\u2013911 (2017).","journal-title":"J. Clin. Oncol."},{"key":"869_CR27","doi-asserted-by":"publisher","first-page":"e084062","DOI":"10.1136\/bmj-2025-084062","volume":"390","author":"C Gomes","year":"2025","unstructured":"Gomes, C. et al. Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis. BMJ 390, e084062 (2025).","journal-title":"BMJ"},{"key":"869_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-025-07636-3","volume":"211","author":"W Jung","year":"2025","unstructured":"Jung, W. et al. Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. Breast Cancer Res. Treat. 211, 293\u2013305 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"869_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan, P. et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur. Heart J. Cardiovasc. Pharmacother. 9, 515\u2013525 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"869_CR30","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474\u20132481 (2006). Early landmark study demonstrating the benefits of using enalapril for cardioprotection in patients undergoing high-dose chemotherapy (anthracycline and non-anthracycline).","journal-title":"Circulation"},{"key":"869_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale, D. et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur. J. Cancer 94, 126\u2013137 (2018).","journal-title":"Eur. J. Cancer"},{"key":"869_CR32","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen, P. A. et al. Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I\u2013guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE trial. Circulation 148, 1680\u20131690 (2023).","journal-title":"Circulation"},{"key":"869_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaccao.2025.06.003","volume":"7","author":"K Loganath","year":"2025","unstructured":"Loganath, K. et al. Anthracycline dose, myocardial injury, and change in left ventricular function in the Cardiac CARE trial. JACC CardioOncol. 7, 725\u2013735 (2025).","journal-title":"JACC CardioOncol."},{"key":"869_CR34","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.125.073322","volume":"152","author":"MG Bonatto","year":"2025","unstructured":"Bonatto, M. G. et al. Sacubitril-valsartan for the prevention of anthracycline cardiotoxicity in patients with elevated cardiac troponin I concentration during chemotherapy: a double-blind randomized placebo-controlled clinical trial: the SARAH trial. Circulation 152, 1742\u20131755 (2025).","journal-title":"Circulation"},{"key":"869_CR35","doi-asserted-by":"crossref","unstructured":"Demissei, B. G. et al. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J. Am. Heart Assoc. 9, e014708 (2020).","DOI":"10.1161\/JAHA.119.014708"},{"key":"869_CR36","doi-asserted-by":"publisher","first-page":"e2546201","DOI":"10.1001\/jamanetworkopen.2025.46201","volume":"8","author":"C Xia","year":"2025","unstructured":"Xia, C. et al. Biomarker-guided cardioprotection for patients treated with anthracyclines: a randomized clinical trial. JAMA Netw. Open 8, e2546201 (2025).","journal-title":"JAMA Netw. Open"},{"key":"869_CR37","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan, P. et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63, 2751\u20132768 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"869_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","volume":"2","author":"JE Liu","year":"2020","unstructured":"Liu, J. E., Barac, A., Thavendiranathan, P. & Scherrer-Crosbie, M. Strain imaging in cardio-oncology. JACC CardioOncol. 2, 677\u2013689 (2020).","journal-title":"JACC CardioOncol."},{"key":"869_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.echo.2025.07.007","volume":"38","author":"JD Thomas","year":"2025","unstructured":"Thomas, J. D. et al. Clinical applications of strain echocardiography: a clinical consensus statement from the American Society of Echocardiography developed in collaboration with the European Association of Cardiovascular Imaging of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 38, 985\u20131020 (2025).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"869_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan, P. et al. Strain-guided management of potentially cardiotoxic cancer therapy. J. Am. Coll. Cardiol. 77, 392\u2013401 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"869_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi, T. et al. Cardioprotection using strain-Guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc. Imaging 16, 269\u2013278 (2023).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"869_CR42","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick, T. H. et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur. Heart J. 45, 4414\u20134424 (2024). GLS-guided cardioprotection resulted in a statistically significant smaller reduction in CMR-LVEF at 12 months compared to usual care.","journal-title":"Eur. Heart J."},{"key":"869_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaccao.2024.05.015","volume":"6","author":"C McCracken","year":"2024","unstructured":"McCracken, C. et al. Predictive performance of cardiovascular risk scores in cancer survivors from the UK Biobank. JACC CardioOncol. 6, 575\u2013588 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaccao.2024.04.010","volume":"6","author":"CH Soh","year":"2024","unstructured":"Soh, C. H., Xiang, R. D., Takeuchi, F. & Marwick, T. H. Use of polygenic risk score for prediction of heart failure in cancer survivors. JACC CardioOncol. 6, 714\u2013727 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jaccao.2025.10.004","volume":"8","author":"PN Fiorica","year":"2026","unstructured":"Fiorica, P. N. et al. Polygenic risk for cardiometabolic and cardiovascular disease in a multiethnic cohort of breast cancer survivors. JACC CardioOncol. 8, 65\u201376 (2026).","journal-title":"JACC CardioOncol."},{"key":"869_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jaccao.2024.05.013","volume":"6","author":"S Jaiswal","year":"2024","unstructured":"Jaiswal, S. et al. Clonal hematopoiesis is associated with cardiomyopathy during solid tumor therapy. JACC CardioOncol. 6, 605\u2013607 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR47","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jaccao.2025.06.006","volume":"7","author":"MA Evans","year":"2025","unstructured":"Evans, M. A. & Walsh, K. Clonal hematopoiesis in cancer and cardiovascular disease. JACC CardioOncol. 7, 470\u2013495 (2025).","journal-title":"JACC CardioOncol."},{"key":"869_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2021.11.008","volume":"4","author":"O Calvillo-Arg\u00fcelles","year":"2022","unstructured":"Calvillo-Arg\u00fcelles, O. et al. Cardiovascular disease among patients with AML and CHIP-related mutations. JACC CardioOncol. 4, 38\u201349 (2022).","journal-title":"JACC CardioOncol."},{"key":"869_CR49","doi-asserted-by":"crossref","unstructured":"Mammadova. J. et al. Clonal hematopoiesis as a molecular risk factor for doxorubicin-induced cardiotoxicity: a proof-of-concept study. JCO Precis. Oncol. 7, e2300208 (2023).","DOI":"10.1200\/PO.23.00208"},{"key":"869_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/HCG.0000000000000097","volume":"18","author":"R Khera","year":"2025","unstructured":"Khera, R. et al. Artificial intelligence to enhance precision medicine in cardio-oncology: a scientific statement from the American Heart Association. Circ. Genom. Precis. Med. 18, e000097 (2025).","journal-title":"Circ. Genom. Precis. Med."},{"key":"869_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45733-x","volume":"15","author":"R Yagi","year":"2024","unstructured":"Yagi, R. et al. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms. Nat. Commun. 15, 2536 (2024).","journal-title":"Nat. Commun."},{"key":"869_CR52","first-page":"11504","volume":"18","author":"EK Oikonomou","year":"2025","unstructured":"Oikonomou, E. K. et al. Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images. Circ. Genom. Precis. Med. 18, 11504 (2025).","journal-title":"Circ. Genom. Precis. Med."},{"key":"869_CR53","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurjpc\/zwad348","volume":"31","author":"JEJ Jacobs","year":"2024","unstructured":"Jacobs, J. E. J. et al. Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur. J. Prev. Cardiol. 31, 560\u2013566 (2024).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"869_CR54","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.amjmed.2025.06.035","volume":"138","author":"IG Scalia","year":"2025","unstructured":"Scalia, I. G. et al. Artificial intelligence for identification of patients with increased risk of severe cancer therapy-related cardiac dysfunction following anthracycline therapy. Am. J. Med. 138, 1561\u20131568 (2025).","journal-title":"Am. J. Med."},{"key":"869_CR55","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1001\/jama.2025.19563","volume":"334","author":"N Mathioudakis","year":"2025","unstructured":"Mathioudakis, N. et al. An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program: a randomized clinical trial. JAMA 334, 2079\u20132089 (2025).","journal-title":"JAMA"},{"key":"869_CR56","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2024.07.002","volume":"6","author":"NL Palaskas","year":"2024","unstructured":"Palaskas, N. L., Siddiqui, B. A. & Deswal, A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 6, 800\u2013803 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR57","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman, R. S., Johnson, D. B. & Balko, J. M. Corticosteroids and cancer immunotherapy. Clin. Cancer Res. 29, 2580\u20132587 (2023).","journal-title":"Clin. Cancer Res."},{"key":"869_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaccao.2025.06.009","volume":"7","author":"E Cheng","year":"2025","unstructured":"Cheng, E. et al. Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy. JACC CardioOncol. 7, 708\u2013721 (2025).","journal-title":"JACC CardioOncol."},{"key":"869_CR59","doi-asserted-by":"publisher","first-page":"11273","DOI":"10.1136\/jitc-2024-011273","volume":"13","author":"P Middha","year":"2025","unstructured":"Middha, P. et al. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. J. Immunother. Cancer 13, 11273 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"869_CR60","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","volume":"47","author":"JR Power","year":"2026","unstructured":"Power, J. R. et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur. Heart J. 47, 1050\u20131062 (2026).","journal-title":"Eur. Heart J."},{"key":"869_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","volume":"25","author":"SH Armenian","year":"2024","unstructured":"Armenian, S. H. et al. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. Lancet Oncol. 25, 235\u2013245 (2024).","journal-title":"Lancet Oncol."},{"key":"869_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1286241","volume":"10","author":"KJ Leger","year":"2023","unstructured":"Leger, K. J. et al. Rationale and design of the Children\u2019s Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy. Front. Cardiovasc. Med. 10, 1286241 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"869_CR63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti, A. W. et al. SGLT2i and primary prevention of cancer therapy\u2013related cardiac dysfunction in patients with diabetes. JACC CardioOncol. 6, 863\u2013875 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR64","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","volume":"5","author":"H Abdel-Qadir","year":"2023","unstructured":"Abdel-Qadir, H. et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol. 5, 318\u2013328 (2023).","journal-title":"JACC CardioOncol."},{"key":"869_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","volume":"33","author":"U Bhalraam","year":"2026","unstructured":"Bhalraam, U. et al. Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 33, 214\u2013226 (2026).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"869_CR66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","volume":"6","author":"H Fonoudi","year":"2024","unstructured":"Fonoudi, H. et al. Functional validation of doxorubicin-induced cardiotoxicity-related genes. JACC CardioOncol. 6, 38\u201350 (2024).","journal-title":"JACC CardioOncol."},{"key":"869_CR67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jaccao.2025.03.007","volume":"7","author":"Y Higashikuni","year":"2025","unstructured":"Higashikuni, Y. et al. Mitigation of doxorubicin cardiotoxicity with synergistic miRNA combinations identified using combinatorial genetics en masse (CombiGEM). JACC CardioOncol. 7, 396\u2013410 (2025).","journal-title":"JACC CardioOncol."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00869-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00869-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00869-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:38:46Z","timestamp":1791826726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00869-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00869-5","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.K. reports research funding from the National Institutes of Health (R01 HL148272, R01 HL152707, R01 HL182015, R01 HL164925, R01 HL163657, K24 HL167127), Patient Centered Outcomes Research Institute (1403-12804) and the American Heart Association Strategically Focused Research Network (869105 and 849569). D.H.L reports research funding from the American Heart Association (24CDA1271837). I.S.H. reports research funding from the American Heart Association Student Scholarship, Okun Family Cardiovascular Scholarship, and Penn Center for Clinical Epidemiology and Biostatistics Stolley Summer Research Fellowship, with B.K. servng as mentor.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}